Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis.
Ikonen. Maaria M; Liu. Bingrong B; Hashimoto. Yuichi Y; Ma. Liqun L; Lee. Kuk-Wha KW; Niikura. Takako T; Nishimoto. Ikuo I; Cohen. Pinchas P
Key Findings
- Humanin binds IGFBP‑3 with high affinity at the heparin‑binding domain
- Humanin blocks IGFBP‑3‑induced death in glioblastoma cells but not in neuroblastoma or primary neurons
- IGFBP‑3 boosts humanin’s protection against amyloid‑beta toxicity in primary neurons
Practical Outcomes
- Humanin may have neuro‑protective potential, especially in contexts involving IGFBP‑3, but the findings are limited to cell and mouse studies. There’s no established dosage or protocol for humans, so biohackers should treat it as experimental and await more safety and efficacy data before using it for brain health.
Summary
Humanin is a tiny protein that can stick to another protein called IGFBP‑3, and this partnership can change how cells survive or die. In some lab tests, humanin helped protect brain cells from Alzheimer‑related damage, especially when IGFBP‑3 was around, but it didn’t work the same way in all cell types. The study shows the interaction is real but still early‑stage, with no clear dosing or human data yet.
Abstract
Insulin-like growth factor-binding protein-3 (IGFBP-3) regulates IGF bioactivity and also independently modulates cell growth and survival. By using a yeast two-hybrid screen to identify IGFBP-3-interacting proteins, we cloned humanin (HN) as an IGFBP-3-binding partner. HN is a 24-aa peptide that has been shown to specifically inhibit neuronal cell death induced by familial Alzheimer's disease mutant genes and amyloid-beta (Abeta). The physical interaction of HN with IGFBP-3 was determined to be of high affinity and specificity and was confirmed by yeast mating, displaceable pull-down experiments with (His)-6-tagged HN, and ligand blot experiments. Co-immunoprecipitation of IGFBP-3 and HN from mouse testes confirmed the interaction in vivo. In cross-linking experiments, HN bound IGFBP-3 but did not compete with IGF-I-IGFBP-3 binding; competitive ligand dot blot experiments revealed the 18-aa heparin-binding domain of IGFBP-3 as the binding site for HN. Alanine scanning determined that F6A-HN mutant does not bind IGFBP-3. HN but not F6A-HN inhibited IGFBP-3-induced apoptosis in human glioblastoma-A172. In contrast, HN did not suppress IGFBP-3 response in SH-SY5Y neuroblastoma and mouse cortical primary neurons. In primary neurons, IGFBP-3 markedly potentiated HN rescue ability from Abeta1-43 toxicity. In summary, we have identified an interaction between the survival peptide HN and IGFBP-3 that is pleiotrophic in nature and is capable of both synergistic and antagonistic interaction. This interaction may prove to be important in neurological disease processes and could provide important targets for drug development.
Study Information
pubmed
2003
2003-10-15T00:00:00.000Z
10.1073/pnas.2135111100
275
25